Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2015 - 2026)
Insight Molecular Diagnostics (IMDX) posted Cash from Investing Activities of -$613000.0 for Q1 2026, up 58.55% sequentially from -$1.5 million in Q4 2025, and down 99.67% YoY from -$188.2 million in Q1 2025.
Insight Molecular Diagnostics (IMDX) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Cash from Investing Activities for 12 years, with the latest figure at -$613000.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 99.67% year-over-year to -$613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 339.12% YoY) and the FY2025 annual result came in at -$3.2 million, down 522.07% from the prior year.
- Cash from Investing Activities grew to -$613000.0 in Q1 2026 per IMDX's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $214000.0 in Q3 2023 and troughed at -$1.6 million in Q1 2022.
- A 5-year average of -$563647.1 and a median of -$349000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities soared 124.91% in 2023, then plunged 1179.17% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$802000.0 in 2022, then soared by 112.84% to $103000.0 in 2023, then plunged by 303.88% to -$210000.0 in 2024, then slumped by 604.29% to -$1.5 million in 2025, then jumped by 58.55% to -$613000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$613000.0, -$1.5 million, and -$1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 164.00 Mn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | -10.15 Bn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -63.43 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | -77.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | -381.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | -25.50 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -122.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | -1.94 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -366.20 Mn |
| 10 | Insight Molecular Diagnostics | 158.03 Mn | 139.50 Mn | 157,000.00 | -779,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -779,000.00 |
| Jun 30, 2026 | -779,000.00 |
| Mar 31, 2026 | -613,000.00 |
| Mar 31, 2026 | -613,000.00 |
| Dec 31, 2025 | -1.48 Mn |
| Dec 31, 2025 | -1.48 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Sep 30, 2025 | -1.05 Mn |
| Jun 30, 2025 | -349,000.00 |
| Jun 30, 2025 | -349,000.00 |
| Mar 31, 2025 | -307,000.00 |
| Mar 31, 2025 | -307,000.00 |
| Dec 31, 2024 | -210,000.00 |
| Dec 31, 2024 | -210,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Sep 30, 2024 | -87,000.00 |
| Jun 30, 2024 | -191,000.00 |
| Jun 30, 2024 | -191,000.00 |
| Mar 31, 2024 | -24,000.00 |
| Mar 31, 2024 | -24,000.00 |